Compare LyondellBasell Industries NV (LYB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Natera Inc. Common Stock — how do they compare? LyondellBasell Industries NV trades at $61.17 (market cap $19.39B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.9× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays a 4.6% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 88 Days and Natera Inc. Common Stock for 0 Days on average.
| LYB | NTRA | |
|---|---|---|
Market Cap | $19.39B | $57.03B |
Volume | 3,160,509 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $425.64 |
52-Week Low | $42.28 | $179.42 |
Typical Hold Time | 88 Days | 0 Days |
Enterprise Value | $30.98B | $56.18B |
Dividend Yield | 4.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.17, up 2.96% today, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $745 million in 2025, with revenue declining to $30.15 billion, though recent quarters have beaten EPS estimates. Analyst sentiment is balanced with a 45% buy and 45% hold rating, and a consensus price target of $68.56 suggests modest upside. The dividend yield remains a key focus amid sector challenges.
The outlook for LYB hinges on earnings recovery and dividend sustainability. Opportunities include operational leverage and favorable market conditions, but risks involve persistent negative margins, high debt levels, and competitive pressures. The stock's performance will likely depend on reversing profitability trends and maintaining investor confidence through consistent dividend payments.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
